azacitidin onko 25 mg/ml pulver zur herstellung einer injektionssuspension
azacitidin stada 25 mg/ml pulver zur herstellung einer injektionssuspension
vidaza
celgene australia pty ltd - azacitidine -
azacitidine accord azacitidine 100mg powder for injection vial
accord healthcare pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine accord is indicated for the treatment of patients with,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ,? chronic myelomonocytic leukemia (cmmol (10-29 percent marrow blasts without myeloproliferative disorder)), ,? acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), ,in whom allogenic stem cell transplantation is not indicated.
celazadine
celgene limited, a bristol myers squibb company - azacitidine 100mg; - powder for injection - 100 mg - active: azacitidine 100mg excipient: mannitol - indicated for the treatment of patients with: - intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss) in whom allogenic stem cell transplantation is not indicated.
vidaza powder for suspension for injection 100 mg /vial
celgene sdn. bhd. - azacitidine -
azacitidine accord
pharmacy retailing (nz) ltd t/a healthcare logistics - azacitidine 100mg (105 mg per vial including 5% manufacturing overage) - powder for injection - 100 mg - active: azacitidine 100mg (105 mg per vial including 5% manufacturing overage) excipient: mannitol - indicated for the treatment of patients with: - intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss). - chronic myelomonocytic leukaemia (cmmol [10%-29% marrow blasts without myeloproliferative disorder]). - acute myeloid leukaemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification, in whom allogenic stem cell transplantation is not indicated.
vidaza injection
key oncologics (pty) ltd - injection - see ingredients - each 1,0 ml suspension contains azacitidine 25,0 mg
azacitidine sandoz azacitidine 100 mg powder for injection vial
sandoz pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine is indicated for the treatment of patients with: ? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.
azacitidine msn azacitidine 100 mg powder for injection vial
juno pharmaceuticals pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine is indicated for the treatment of patients with: ? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.